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GNAS encodes the stimulatory G protein alpha-subunit (Gsα) and its large variant
XLαs. Studies have suggested that XLαs is expressed exclusively paternally. Thus, XLαs
deficiency is considered to be responsible for certain findings in patients with paternal
GNAS mutations, such as pseudo-pseudohypoparathyroidism, and the phenotypes
associated with maternal uniparental disomy of chromosome 20, which comprises
GNAS. However, a study of bone marrow stromal cells (BMSC) suggested that XLαs
could be biallelically expressed. Aberrant BMSC differentiation due to constitutively
activating GNAS mutations affecting both Gsα and XLαs is the underlying pathology
in fibrous dysplasia of bone. To investigate allelic XLαs expression, we employed next-
generation sequencing and a polymorphism common to XLαs and Gsα, as well as
A/B, another paternally expressed GNAS transcript. In mouse BMSCs, Gsα transcripts
were 48.4 ± 0.3% paternal, while A/B was 99.8 ± 0.2% paternal. In contrast, XLαs
expression varied among different samples, paternal contribution ranging from 43.0
to 99.9%. Sample-to-sample variation in paternal XLαs expression was also detected
in bone (83.7–99.6%) and cerebellum (83.8 to 100%) but not in cultured calvarial
osteoblasts (99.1 ± 0.1%). Osteoblastic differentiation of BMSCs shifted the paternal
XLαs expression from 83.9 ± 1.5% at baseline to 97.2 ± 1.1%. In two human
BMSC samples grown under osteoinductive conditions, XLαs expression was also
predominantly monoallelic (91.3 or 99.6%). Thus, the maternal GNAS contributes
significantly to XLαs expression in BMSCs but not osteoblasts. Altered XLαs activity
may thus occur in certain cell types irrespective of the parental origin of a GNAS defect.
Keywords: GNAS, stimulatory G protein, imprinting, osteoblasts, bone marrow stromal cells, fibrous dysplasia
of bone
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INTRODUCTION
GNAS is an imprinted gene encoding the alpha-subunit of the
stimulatory G protein (Gsα), a signaling protein mediating the
actions of many endogenous molecules via generation of cAMP
(Plagge et al., 2008; Weinstein et al., 2004; Mantovani et al., 2016).
Loss-of-function mutations or epigenetic alterations of GNAS are
responsible for different human diseases that involve abnormal
skeletal development, metabolism, and hormone actions, such as
pseudohypoparathyroidism Ia (MIM: 103580). Gain-of-function
GNAS mutations affecting the activity of Gsα are found in a
variety of benign and malignant tumors, as well as in patients
with fibrous dysplasia of bone and McCune-Albright syndrome
(MIM: 174800). GNAS gives rise to multiple additional products
showing exclusively maternal or paternal expression (Bastepe,
2007; Kelsey, 2010). The extra-large G-alpha subunit (XLαs) is
a variant of Gsα that uses a separate promoter and a unique
first exon that splices onto Gsα exon 2 (Kehlenbach et al., 1994;
Hayward et al., 1998). Hence, XLαs is partly identical to Gsα and
can mimic the latter regarding cAMP generation (Klemke et al.,
2000; Bastepe et al., 2002); however, XLαs mediates additional
cellular actions, such as stimulation of IP3/PKC signaling and
inhibition of clathrin-mediated endocytosis (He et al., 2015; He
et al., 2017; He et al., 2019).
XLαs expression has been shown to occur exclusively from
the paternal allele (Hayward et al., 1998), unlike Gsα, which is
biallelic in most tissues. Thus, a GNAS mutation is predicted to
affect XLαs only if it resides on the paternal allele. For example,
the GNAS mutations causing pseudohypoparathyroidism
type-1a are inherited maternally (Davies and Hughes, 1993)
and, therefore, disrupt one copy of Gsα without affecting
XLαs. In contrast, the same mutations in patients with
pseudo-pseudohypoparathyroidism are inherited paternally
and thus disrupt both XLαs and one copy of Gsα. The
severe intrauterine growth retardation observed in pseudo-
pseudohypoparathyroidism is attributed to XLαs deficiency
(Richard et al., 2013). In addition, recent studies have described
patients with maternal uniparental disomy of chromosome 20
(matUPD20, MIM: 617352)—the genomic region comprising
GNAS—who display Silver-Russell syndrome-like features
including perinatal growth retardation and intractable feeding
difficulties (Mulchandani et al., 2016; Kawashima et al., 2018).
The phenotypes associated with matUPD20 are similar to those
observed in children with large paternal GNAS deletions (Aldred
et al., 2002; Genevieve et al., 2005) and thus attributed largely
to XLαs deficiency. Moreover, a recent study described an adult
patient with hypophosphatemia and osteopetrosis who carried
a nonsense mutation within the first XLαs exon (Chen et al.,
2020). This defect was also paternally inherited, consistent with
the evidence that XLαs is expressed from the paternal allele.
Nevertheless, a study demonstrated XLαs expression from both
alleles in human bone marrow stromal cells (BMSCs) from
normal and fibrous dysplastic tissues (Michienzi et al., 2007).
The analyzed BMSCs were clonogenic, and interestingly, Gsα
expression was also shown to be allelically, but randomly,
skewed, suggesting that the observed alterations in allelic XLαs
and Gsα expression may have been secondary to the cloning.
BMSCs include mesenchymal progenitor/stem cells capable
of differentiating into multiple different lineages. Gsα signaling
promotes the commitment of mesenchymal progenitors into
the osteoblast lineage while restricting osteoblast differentiation
(Wu et al., 2011). Accordingly, a gain-of-function GNAS
mutation results in the aberrant differentiation of BMSCs into
osteoblasts, the primary cellular mechanism underlying fibrous
dysplasia of bone (Xiao et al., 2019). The causative GNAS
mutations are heterozygous and located in exons shared by
Gsα and XLαs (Weinstein et al., 1991; Schwindinger et al.,
1992). It has been shown that these mutations increase the
baseline activity of not only Gsα but also XLαs (Klemke
et al., 2000; He et al., 2015). Thus, whether XLαs is expressed
monoallelically or biallelically in BMSCs could have strong
implications for fibrous dysplasia pathogenesis. Moreover, as
mentioned above, the phenotypes attributed to the loss of
XLαs in vivo are based on the notion that XLαs is expressed
in an exclusively paternal manner. If, however, tissue-specific
biallelic XLαs expression exists, then our understanding of its
physiological roles and its involvement in GNAS-related diseases
may have to be revised.
In this study, we investigated the allele-specific expression
of XLαs in non-clonal mouse and human BMSCs and
other cells and tissues. We quantitated allelic contribution
by employing next-generation sequencing (NGS) of RT-PCR
amplicons carrying a polymorphism. Our results revealed a
significant contribution from the maternal GNAS allele in non-
differentiated BMSCs but not in osteogenically differentiated
BMSCs or calvarial osteoblasts.
MATERIALS AND METHODS
Mice
XLαs knockout (XLKO) mice, carrying a disruption in the
first exon of XLαs, have been described (Plagge et al., 2004)
and maintained in the CD1 background. Wildtype 129/Sv and
C57BL/6 mice (Jackson Laboratory) were mated to obtain F1
generation hybrid offspring. Both male and female mice were
analyzed. All mice experiments were conducted according to the
accepted standards of the Institutional Animal Care and Use
Committee and approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care.
Restriction Digestion for Confirming
Maternal and Paternal XLKO Samples
and Determining the Parental
Contribution of Gnas Transcripts
The methylation-sensitive restriction enzyme HpaII (New
England Biolabs) was used to digest the genomic DNA (1
µg) from tails of offspring derived from matings between
heterozygous XLKO mice. Digested DNA was purified using the
QIAquick PCR purification kit (Qiagen) and eluted with 30 µl
water. Then, 2 µl of each sample was used as a template for
genotyping PCR, as described (Plagge et al., 2004). To determine
the parental contribution of Gsα, XLαs, and A/B transcripts,
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RT-PCR products from tissues of mice heterozygous for the C-to-
G SNP in exon 11 (rs13460569) were incubated (37◦C, 6 h)
with BanII (New England BioLabs) and analyzed by agarose gel
electrophoresis, as described (Tafaj et al., 2017).
Mouse Primary Cell Cultures and
Osteogenic Differentiation
Mouse BMSCs were harvested by flushing the marrow out of long
bones (femurs and tibias) of 14 week-old mice, as described (Wu
et al., 2011). Cells were plated at a density of 0.5× 106 to 1× 106
cells/cm2 and cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) (Gibco, United States) containing 10% Fetal Bovine
Serum (FBS) (Hyclone, United States). Non-adherent cells were
washed off, and the adherent cells were cultured for 1 week,
followed by RNA extraction. Primary calvarial pre-osteoblasts
were isolated at postnatal day five by serial collagenase digestion,
as described (Mariot et al., 2011). Cells were seeded at a density of
10,000 cells/well in 12-well plates and cultured in Modified Eagle’s
Medium (MEM) (Gibco, United States) containing 10% FBS.
Osteoblastic differentiation was induced by adding ascorbic acid
(50 µg/ml) and β-glycerol phosphate (10 mM) (Sigma-Aldrich),
as described (Wu et al., 2011). Differentiation medium for BMSCs
also included 10 nM dexamethasone (Sigma-Aldrich).
Human BMSCs
Cells were obtained from participants who underwent total
hip arthroplasty surgery at Boston Medical Center between
2019 and 2020. All human research was done under a Boston
University School of Medicine Institutional Research Board
Approved protocol: “Bone Tissues Repository,” IRB Number: H-
35199, with patients’ consents per current HIPAA regulations
prior to surgery and specimen collection. The femoral head and
reamings, from the coring of the acetabulum, were collected
during total hip arthroplasty. After multiple washes using DPBS
(Hyclone Laboratories) containing an antibiotic-antimycotic
mixture (Thermo Fischer Scientific) cells were suspended in
DPBS. 24 million cells/well were seeded in each well of 6-well
plates (Corning Inc.), treated with Animal Component-Free Cell
Attachment Substrate (Stem Cell Technologies) diluted 1:150 in
DPBS. Cells were cultured in an incubator at 37◦C, 5% CO2,
and > 90% humidity. A half media change was performed
on day 4 and a full media change on day six after plating.
Cells were then grown in basal medium supplemented with
osteoinductive factors (Stem Cell Technologies) for 21 days
before RNA extraction.
Total RNA Extraction, RT-PCR and
qRT-PCR Amplification
Total RNA of mouse organs was extracted by using Trizol R©
Reagent (Life Technologies) followed by the Qiagen RNeasy R©
Plus Mini Kit. Total RNA of human BMSCs was extracted using
4 M Guanidine-HCl, 1% Triton X-100, 10 mM Tris HCl, 2 mM
EDTA (pH 7.4). cDNA was synthesized using the New England
Biolabs ProtoScript II First-strand cDNA synthesis kit.
Total RNA of calvarial osteoblasts and BMSC were isolated
by using the Qiagen RNeasy R© Plus Mini kit. One µg total RNA
was reverse transcribed using the Superscript III First-Strand
Synthesis System (Invitrogen) and then subjected to PCR using
the PCR Master Mix (Promega). PCR mixture contained 2 µL
cDNA in a final volume of 20µL. PCR included 1 cycle at 94◦C
for 5 min, followed by 40 cycles of 94◦C for 30 s, 56◦C for 30 s
and 72◦C for 2 min, and a final extension at 72◦C for 7 min. For
XLαs and A/B, nested PCR was performed using, as template, the
primary PCR product diluted 1:10 or 1:2, respectively. qRT-PCR
included 1 cycle at 50◦C for 2 min and 94◦C for 15 min, followed
by 50 cycles of 94◦C for 15 s, 60◦C for 20 s, and 72◦C for 20 s. The
PCR primers are listed in Supplementary Table 1.
Sequence Analysis of RT-PCR Products
The RT-PCR products were purified by the QIAquick PCR
Purification kit. Both Sanger sequencing and NGS was performed
at the Massachusetts General Hospital DNA Core. Primers for
Sanger sequencing were the same as PCR primers. For NGS,
purified PCR products were first fragmented and then subjected
to NGS library preparation, followed by sequencing on the
Illumina MiSeq. The reads were analyzed following automated de
novo sequence assembly. The authenticity of the amplicons was
confirmed by the unique first exon sequences of XLαs and A/B.
To determine the relative contributions of the parental alleles,
the ratio of reads containing one of the nucleotides to the total
number of reads at rs13460569 (mouse) or rs7121 (human) was
calculated for each sample.
Genomic DNA Methylation Analysis
Genomic DNA (600 ng) from non-differentiated and
differentiated BMSCs (the same samples as those used for
allelic XLαs expression) was treated with sodium bisulfite by
using the EZ DNA Methylation gold kit (Zymo Research), and
the converted DNA was recovered in 10 µl. Primary PCR was
performed using 2 µl bisulfite-treated DNA as template in a
total reaction volume of 40 µl. The nested PCR used 2 µl of
the primary PCR product. PCR included initial denaturation
at 95◦C for 5 min, 35 cycles of 95◦C for 30 s, 56◦C for 30 s,
72◦C for 30 s, and final extension at 72◦C for 10 min. Primers
for the region within XLαs exon were previously described
(Liu et al., 2000). Primers for the XLαs promoter were as
follows: 5′-GATGGGGAGGGAGGTTTTTA-3′ (forward) and
5′–AAAACTAAAACCCAAAACCATAACT-3′ (reverse). Nested
PCR used the same forward primer together with the following
reverse primer: 5′-TCACCTTCCTAATTACACTTACCC-3′. The
amplicons were subjected to NGS at the Massachusetts General
Hospital DNA Core. To calculate the degree of methylation,
paired-end NGS reads were aligned using the BWA-MEM
algorithm to a reference reflecting bisulfite-induced alterations
except for the CpG dinucleotides. The FreeBayes variant
detector was then used to identify each C-to-T variant and the
allelic balance (i.e., C is methylated and T non-methylated).
BWA-MEM and FreeBayes were run on the Galaxy platform1
(Afgan et al., 2018).
1https://usegalaxy.org/
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Statistical Analyses
Outliers were identified by the Grubbs test and excluded. One-
way ANOVA followed by Tukey’s post-hoc test was used to
analyze the differences among three or more groups. The
student’s t-test (two-tailed) was used between two groups.
The paired Student’s t-test (two-tailed) was employed for the
differences between non-differentiated and differentiated BMSC
samples. Wilcoxon rank-sum test was performed to compare the
groups regarding the distribution of the data. One-sample t-test
was performed to determine the significance of the difference
between the maternal expression in non-differentiated BMSCs
and the hypothetical value of 0%. P < 0.05 were considered
significant. Analyses were performed using Prism 8 (GraphPad).
RESULTS
Comparing XLαs mRNA Levels in
Wildtype and XLKO Mice to Determine
Allele-Specific XLαs Expression
To examine the allelic expression profile of XLαs in bone,
we first employed adult XLKO mice, because disruption of
paternal XLαs first exon in those mice was reported to cause a
dramatic reduction of XLαs transcript levels in various tissues
(Plagge et al., 2004). The maternal, paternal, and homozygous
XLKO mice were derived from matings between heterozygous
XLKO mice. The previously described genotyping approach
for these mice (Plagge et al., 2004) is unable to distinguish
maternal from paternal XLKO mice. We thus performed
genotyping before and after digestion of genomic DNA with the
methylation-sensitive restriction enzyme HpaII, which cleaves
the unmethylated, paternal allele at multiple sites and, thereby,
prevents it from serving as a template in PCR (Figure 1A). The
PCR performed following the HpaII digest detected only the
intact maternal allele and allowed us to identify the parental
origin of the targeted allele. In the absence of the HpaII digestion,
heterozygotes showed a double band, the upper one representing
the targeted allele, and wildtype (WT) and homozygous XLKO
mice yielded only the smaller or the larger product, respectively
(Figure 1B). Following the HpaII digest, only the smaller PCR
product was detected in WT and paternal XLKO mice, and
only the larger PCR product was observed in homozygous and
maternal XLKO mice (Figure 1B).
qRT-PCR using total RNA from femur samples (bone marrow
flushed out) showed that XLαs mRNA levels were significantly
lower in paternal XLKO mice than in WT or maternal XLKO
littermates (Figure 1C). While this finding was consistent with
the silencing of the maternal allele in bone, other comparisons







FIGURE 1 | XLαs mRNA levels in maternal and paternal XLαs knockout mice to examine the allele-specific expression of XLαs. (A) Depiction of the normal and
targeted (triangle) Gnas alleles comprising the first exon of XLαs in mice in which either the paternal (above) or the maternal (below) allele is targeted. The methylation
(CH3)-sensitive restriction enzyme HpaII cleaves the unmethylated (paternal) allele at multiple sites. Thus, the PCR performed using the HpaII-digested DNA detects
only the intact maternal allele. (B) PCR products from WT (wildtype), homozygous (hom), maternal (mat), and paternal (pat) DNA samples obtained before (−) or after
(+) the HpaII restriction enzyme. Note that the targeted allele produces a larger product. PCR products from maternal and homozygous XLKO after the HpaII digest
are larger than those from paternal XLKO and WT. Arrows indicate the 1,000- and 500-bp bands in the DNA ladder. (C) Box and whisker plots showing XLαs mRNA
levels in bones from 14-week-old WT, maternal XLKO, paternal XLKO, and homozygous XLKO mice. (D,E) Female and male mice plotted separately. RNA was
obtained from femurs after flushing out the bone marrow. qRT-PCR was performed with β-Actin as reference. Data were normalized to wildtype. *p < 0.05; using
one-way ANOVA, followed by Tukey’s post-hoc test for pairwise comparisons; n = 18 WT (8 female and 10 male), 16 maternal XLKO (5 female and 11 male), 17
paternal XLKO (6 female and 11 male), and 16 homozygous XLKO (10 female and 6 male).
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differences could be detected between the levels in homozygous
XLKO mice and either WT or maternal XLKO (Figure 1C).
Separate analysis of males and females did not reveal any
significant differences between the groups, owing partly to the
reduced sample sizes (Figures 1D,E).
Intercrosses of C57BL/6 and 129/Sv
Mice Allows Identification of Parental
Gnas Alleles
To determine allelic XLαs expression without relying on gene
disruption, we then took advantage of a polymorphism located
in Gnas exon 11, as described (Tafaj et al., 2017). The 129/Sv
mice carry a cytosine (C), while C57BL/6 and CD1 strains
carry a guanine (G) in the Gsα transcript (NM_201616.2,
c.1009; rs13460569). We thus set up matings between 129/Sv
males and C57BL/6 females and analyzed the offspring at
age 14 weeks. RT-PCR using total RNA isolated from BMSCs
amplified specific products from Gsα, XLαs, and A/B transcripts
including the exon 11 polymorphism, and those products were
then digested with BanII, a restriction enzyme that recognizes the
polymorphism and differentially cleaves the paternally-derived
C-containing products (Figure 2A). BanII partially cleaved
the Gsα-derived products (Figure 2B), consistent with the
previously demonstrated biallelic expression of this Gnas product
in multiple tissues (Tafaj et al., 2017). In contrast, the A/B-derived
products were completely cleaved, indicating that, consistent
with previous observations (Tafaj et al., 2017), the A/B expression
was nearly completely paternal (Figure 2B). A significant portion
of the XLαs-derived RT-PCR products was cleaved; however, a
faint band representing non-cleaved products were also visible,
suggesting that XLαs expression may not be exclusively paternal
in BMSCs (Figure 2B).
NGS to Quantitate the Parental Origin of
XLαs Expression
To have a quantitative assessment of XLαs expression from
paternal vs. maternal Gnas alleles, we then subjected the RT-
PCR products to NGS. Providing sequence data from thousands
of molecules from each PCR amplicon, this approach revealed
the origin of each read with respect to its parental origin, i.e.,
C-containing reads are derived from the paternal allele, while
G-containing reads are from the maternal allele. We analyzed
BMSCs and femur, as well as cerebellum, in which XLαs was
shown to be expressed at high levels (Pasolli et al., 2000).
As shown in Figures 2C–E and Supplementary Table 2, the
Gsα products contained ∼50% C-containing products in all the
tissues tested, thus confirming the biallelic transcription of Gsα.
The C- containing reads in A/B transcript-derived PCR products
were nearly 100% of the total in all three tissues, indicating
exclusive paternal expression. In XLαs-derived RT-PCR products,
however, the ratio of C-containing to G-containing reads varied
significantly from sample to sample, particularly in BMSCs,
                 
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FIGURE 2 | The use of an exon 11 C-to-G polymorphism reveals significant sample-to-sample variation in allelic XLαs expression. (A) Schematic presentation of
XLαs, A/B, and Gsα transcripts in the mouse Gnas locus. The cytosine nucleotide in SNP rs13460569 introduces a BanII restriction site. The intercrosses of
C57BL/6 and 129/Sv mice were designed, such that the BanII site is present on the paternal Gnas allele (i.e., inherited from the 129/Sv fathers). The expected sizes
are depicted for each RT-PCR amplicon below. (B) Agarose gel electrophoresis of BanII-digested and undigested RT-PCR amplicons, using total RNA of BMSCs
from 14-week old F1 generation mice. First lane, DNA ladder. (C–E) The percentage of C-containing (paternal) NGS reads relative to the total number of reads.
Complete data (C) and data from females (D) and males (E) are shown separately from individual mice. The RT-PCR products using total RNA from BMSCs, bone,
and cerebellum of 14 week-old F1 generation mice were subjected to NGS. ∗p < 0.05 regarding the difference between the distribution of data points for XLαs and
A/B (the Wilcoxon rank-sum test).
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FIGURE 3 | Allele-specific XLαs expression in cultured preosteoblasts and osteoblasts is almost exclusively paternal. The mRNA levels of osteoblast markers Ibsp
(A), Bglap (B), and Dmp1 (C) were measured to confirm osteoblastic differentiation of calvarial preosteoblasts. qRT-PCR was used with β-actin as reference control.
*p < 0.05; ***p < 0.001 vs. non-differentiated by two-tailed Student’s t-test (n = 7). (D) Percent of C-containing (paternal) NGS reads in RT-PCR amplicons from
Gsα, XLαs, and A/B transcripts in non-differentiated and 14 day-differentiated preosteoblasts. Data are from individual F1 mice of C57BL/6 × 129/Sv intercrosses.
ranging from 43.0 to 99.9% among six independent samples
(Figures 2C–E and Supplementary Table 2). Modest sample-
to-sample variation was also detectable in bone (83.7–99.6%)
and cerebellum (83.8–100%; Figures 2C–E and Supplementary
Table 2), and the variation observed in XLαs-derived products
was significantly different from the variation observed in A/B-
derived products in all three tissues.
Allelic XLαs Expression in Differentiated
Osteoblasts
As another type of cultured primary cells, we examined mouse
calvarial pre-osteoblasts from the C57BL/6-129/Sv intercrosses
before and after culturing them under osteogenic conditions for
14 days. qRT-PCR experiments confirmed the osteoblast markers
bone sialoprotein (Ibsp), osteocalcin (Bglap), and dentin matrix
protein-1 (Dmp1) (Figures 3A–C). The NGS analysis of Gsα-
derived RT-PCR products showed comparable numbers of C- and
G-containing reads in both non-differentiated and differentiated
cells, indicating biallelic expression (Figure 3D). In contrast,
C-containing reads were nearly 100% of total reads for both XLαs
and A/B products in those cells and there was no evidence of
variation in the allelic XLαs expression (Figure 3D).
We then analyzed a new set of BMSCs both before and after
osteogenic differentiation, which was confirmed by measuring
the levels of Ibsp and Dmp1 mRNA (Figures 4A,B). In this
new set of samples, while the paternal expression of A/B was
nearly 100%, the paternal XLαs expression varied modestly
from 80.3 to 88.5% of total (Figure 4C and Supplementary
Table 3). This finding confirmed the significant contribution
from the maternal allele to XLαs expression (mean = 16.1± 1.5%,
p < 0.001 vs. the hypothetical 0% maternal). Combined, the
mean maternal expression in all our BMSC samples (n = 11) was
17.6 ± 4.9% (95% confidence interval: 6.6–28.6%; p < 0.01 vs.
the hypothetical value of 0%). Strikingly, when cells were grown
under osteoinductive conditions for 2 weeks, the expression of
XLαs shifted in the favor of the paternal allele, from 83.9 ± 1.5%
paternal in non-differentiated to 97.2 ± 1.1% paternal in
differentiated BMSCs (Figure 4C).
We also tested human BMSCs from two unrelated individuals,
employing a C-to-T polymorphism located in GNAS exon 5
(rs7121, chr20:58903752, hg38). The samples (#231 and #236)
Frontiers in Genetics | www.frontiersin.org 6 June 2021 | Volume 12 | Article 680537
fgene-12-680537 June 11, 2021 Time: 17:33 # 7








   
A B C
D E
FIGURE 4 | Allele-specific XLαs expression becomes increasingly paternal with osteoblastic differentiation of BMSCs. The mRNA levels of osteoblast markers Ibsp
(A) and Dmp1 (B) were measured to confirm osteoblastic differentiation of BMSCs. qRT-PCR was used with β-actin as reference control. **p < 0.01 vs.
non-differentiated by two-tailed Student’s t-test (n = 5). (C) Percent of C-containing (paternal) NGS reads in XLαs RT-PCR amplicons before and after differentiation
toward the osteoblast lineage. Data are from individual F1 intercrosses of C57BL/6 × 129/Sv. **p < 0.01 vs. non-differentiated by paired Student’s t-test. (D) Sanger
sequencing traces showing the heterozygous GNAS exon 5 C-to-T polymorphism in two separate human BMSC (hBMSC) samples. (E) Percentage of T-containing
reads relative to total reads obtained from the NGS of Gsα and XLαs RT-PCR products. The total number of NGS reads for each amplicon is indicated. T-containing
reads for #231-Gsα: 4017 (forward), 17727 (reverse); #231-XLαs: 1179 (forward), 21533 (reverse); #236-Gsα: 6522 (forward), 33294 (reverse); #236-XLαs: 922
(forward), and 20448 (reverse).
were cultured under osteogenic conditions before examining the
relative contribution of each allele to Gsα and XLαs expression.
Sanger sequencing of Gsα-derived RT-PCR products revealed
that both samples were heterozygous for the polymorphism
(Figure 4D). Subsequent NGS of those products showed
comparable numbers of reads containing either C or T at the
polymorphic site, with T-containing reads making up 50.4 or
54.0% of total reads (Figure 4E). In contrast, NGS of XLαs-
derived RT-PCR products yielded 91.3 and 99.6% T-containing
reads in #231 and #236, respectively (Figure 4E), indicating
predominantly or nearly exclusively monoallelic expression.
Differential DNA Methylation at the
Genomic XLαs Locus
The genomic region comprising the first XLαs exon is
differentially methylated, consistent with the monoallelic
expression of XLαs transcripts. We thus analyzed the degree
of methylation in the previously described region (Liu et al.,
2000). PCR amplicons derived from bisulfite-treated genomic
DNA were subjected to NGS, thus allowing accurate relative
quantification of unmethylated (converted to T) and methylated
(protected) CpGs at multiple sites. The results, however, showed
no significant differences in the overall degree of methylation
between non-differentiated and differentiated BMSCs (average
of 55.7 and 55.8% of total, respectively; Figures 5A,B). We
also analyzed the methylation status of a second region,
which overlaps the XLαs promoter (Williamson et al., 2006;
Aydin et al., 2009; Figure 5A). The methylation of individual
CpGs and the average methylation across the amplicon were
comparable between non-differentiated and differentiated
BMSCs (average 46.2 and 47.7%, respectively; Figure 5B and
Supplementary Table 4).
DISCUSSION
In this study, we examined the parental contribution of GNAS
allele to XLαs expression in non-clonal BMSCs and other
murine tissues. In bone and cultured calvarial osteoblasts,
XLαs expression was nearly exclusively paternal. In contrast,
substantial maternal contribution was detected in non-
differentiated BMSCs. The expression of Gsα was biallelic
and that of A/B was virtually exclusively paternal in all the
investigated cells/tissues.
To assess allelic XLαs expression, we first measured XLαs
mRNA levels in paternal, maternal, and homozygous XLKO mice
and their wildtype littermates. A similar approach has been used
to measure the monoallelic expression of Gsα in certain tissues,
such as proximal renal tubules (Turan et al., 2014). However,
although the results appeared broadly consistent with an allelic
bias of XLαs expression in bone, the mRNA levels varied widely,
even within the same genotype. As this approach relied on the
loss of XLαs production from the disrupted allele, this variability
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FIGURE 5 | Methylation of XLαs promoter and DMR in mouse BMSCs.
(A) The genomic region comprising XLαs exon 1 and the promoter, including
exon 1 of the GNAS antisense (also known as Nespas). The analyzed regions
are indicated by horizontal bars. The five CpGs analyzed at XL DMR span
chr2:174300870-174300902 (mm 10) and the 30 CpGs analyzed at XLαs
promoter span chr2:174297234-174297623 (mm 10). Exons (open: coding,
closed: non-coding) and introns are depicted by boxes and connecting lines,
respectively. The direction of transcription is indicated by arrows. The female
germline imprint previously identified in this region is indicated. (B) Average
methylation across the analyzed region in individual non-differentiated and
osteogenically differentiated mouse BMSC samples. The differences are not
statistically significant; p = 0.92 for the XLαs DMR and p = 0.62 for the XLαs
promoter (paired t-test, 2-tailed).
may reflect some detectable levels of XLαs mRNA being made
from the latter allele, in addition to the outbred CD1 background
in which XLKO mice had to be maintained (Plagge et al., 2004).
As an alternative approach, we utilized a known
polymorphism in the mouse Gnas locus. We subjected the
RT-PCR products to NGS, since it has been utilized for
quantitatively detecting mosaic single nucleotide variants in
clinical settings (Narumi et al., 2013). Indeed, NGS allowed
us to obtain sequence information from thousands of reads
and distinguish the allelic origin of the products. We analyzed
the allele-specific XLαs and Gsα expression in human BMSCs
similarly, using NGS and a common polymorphism (Campbell
et al., 1994). In the human samples, genotypes of the donors’
parents were unknown. Therefore, although we could quantify
the allele-specific expression, we were unable to determine the
parental origin.
Michienzi et al. examined clonal BMSCs from wildtype
and fibrous dysplasia-derived samples and showed evidence of
biallelic XLαs expression, as well as parental Gsα expression that
appeared asymmetrical (Michienzi et al., 2007). We analyzed
non-clonal BMSCs passaged no more than three times. In total,
we found biallelic XLαs expression in one sample and substantial
deviation from monoallelic expression in seven samples, while
the results from the remaining three samples were consistent with
nearly exclusive paternal expression. There might be an influence
of cell culture on our results. Nonetheless, no such variation was
observed among our calvarial osteoblast samples, which were also
cultured. Moreover, in BMSCs that were differentiated in culture
toward the osteoblast lineage, the XLαs expression became more
significantly paternal, arguing against the possibility that culture
conditions caused a relaxation of XLαs imprinting.
A plausible explanation for the observed variation in allelic
XLαs expression in our BMSC samples may be cellular
heterogeneity, as BMSCs are known to be heterogeneous with
variable representations of cell types in different samples (Kfoury
and Scadden, 2015). Therefore, it is likely that XLαs is expressed
biallelically in a certain subset of cells in the bone marrow, as
well as in some other tissues. Regarding the study by Michienzi
et al. (2007), the analyzed clonogenic BMSCs may have been
derived from the cell-type(s) in which XLαs expression is biallelic.
Alternatively, the maternal XLαs promoter may be active in
all cell types in the BMSC samples but at a lower level than
the paternal XLαs promoter. However, when considering the
heterogeneity of BMSCs regarding cell types and the variation
we observed among the samples, the former possibility appears
more plausible. The finding that substantial XLαs expression
occurs from the maternal allele in certain cell types has important
implications. The physiological roles of XLαs in vivo have thus
far been deduced from findings in mice or patients in whom the
paternal XLαs allele is disrupted alone, assuming a complete loss
of this protein in all tissues. According to our results, some of
those interpretations could be at least partially incorrect.
We found paternal XLαs expression in mouse whole bones,
although significant but modest sample-to-sample variation
was observed in the parental contribution, as opposed to A/B
expression, which appeared consistently ∼100% paternal. XLαs
is substantially expressed in the cerebellum (Pasolli et al., 2000).
We also detected mild variation in the allelic expression of XLαs
among our mouse cerebellum samples, suggesting that in both
bone and cerebellum, there may be a small subset of cells in which
XLαs expression is biallelic.
Unlike the allelic expression data, we did not detect
differences in DNA methylation between non-differentiated and
differentiated BMSCs. The data for the methylation analysis
refelected all the cells in the sample while the expression
data originated only from cells that express XLαs. Since the
methylation differences are expected to occur only in XLαs-
expressing cells, they may have remained under our detection
limit, particularly if those cells are scarce. Alternatively, other
methylated regions or regulatory events may dictate the allelic
shift of XLαs expression during osteogenic differentiation. The
analyzed XLαs promoter region lies within a germline imprint
including the Gnas antisense exon 1 (also known as Nespas;
Coombes et al., 2003; see Figure 5A). It is possible that a different
part of this germline imprint regulates the XLαs promoter
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activity. Also, a methylation-independent mechanism may be
involved, considering that an “uncoupling” of allelic silencing
and promoter DNA methylation has been described for the
Nespas-mediated regulation of the Nesp55 promoter activity
(Williamson et al., 2011). The regulation of allelic expression in
this locus is certainly complex. It is also worth mentioning that
the analyzed XLαs promoter region is orthologous to human
GNAS-AS2, a region shown to be severely hypomethylated (i.e.,
loss of methylation) in patients with both sporadic and familial
pseudohypoparathyroidism type-Ib (MIM: 603233) (Rochtus
et al., 2016). Whether the hypomethylation is associated with
biallelic XLαs expression is unknown.
Tissue- or cell type-specificity has been shown for the
monoallelic expression of some transcripts, including Gsα, which
is biallelic in most but predominantly maternal in some tissues
(Yu et al., 1998). Conversely, Dlk1, a product of the imprinted
gene cluster on chromosome 14, is paternally expressed nearly in
all tissues but exhibits biallelic expression in postnatal neural stem
cells and niche astrocytes (Ferron et al., 2011). Our observations
regarding the allelic expression of XLαs are analogous to those
documented for Dlk1 and supports the likelihood that XLαs is
expressed biallelically in certain cell types. Identification of those
cells may reveal important novel roles of XLαs.
In summary, our findings indicate that the maternal GNAS
allele contributes significantly to XLαs expression in BMSCs.
Thus, altered XLαs actions could be involved in at least some
of the phenotypes associated with GNAS mutations even if the
mutation is maternal.
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